S&P Futures
3,789.75+27.50(+0.73%)Dow Futures
30,928.00+208.00(+0.68%)Nasdaq Futures
12,908.50+106.25(+0.83%)
Co-Diagnostics, Inc. (CODX)
10.75 +0.21 (1.99%)
Before hours: 8:09AM EST
Chart Events
Performance Outlook
| Previous Close | 10.16 |
| Open | 10.40 |
| Bid | 10.40 x 900 |
| Ask | 10.90 x 800 |
| Day's Range | 10.36 - 11.18 |
| 52 Week Range | 1.10 - 30.99 |
| Volume | 2,086,143 |
| Avg. Volume | 1,946,133 |
| Market Cap | 297.957M |
| Beta (5Y Monthly) | -1.77 |
| PE Ratio (TTM) | 9.39 |
| EPS (TTM) | 1.12 |
| Earnings Date | Nov 16, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.00 |
- Motley Fool
These Were the 5 Best Diagnostics Stocks of 2020
It's hard to think of an industry that was more impacted by the 2020 COVID pandemic than diagnostics. The often-overlooked part of the healthcare system sprang into action, testing more than 250 million people last year in the U.S. alone. Co-Diagnostics (NASDAQ: CODX), Aspira Women's Health (NASDAQ: AWH), Fulgent Genetics (NASDAQ: FLGT), GenMark Diagnostics (NASDAQ: GNMK), and Natera (NASDAQ: NTRA) were the five best-performing diagnostics companies last year among those with a market cap above $200 million.
- PR Newswire
Co-Diagnostics to Present at H.C. Wainwright BioConnect 2021 Virtual Conference
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will participate in a panel discussion on diagnostics and devices hosted by Scott Gottlieb, M.D., at the H.C. Wainwright & Co. BioConnect 2021 Conference, being held January 11-14.
- PR Newswire
Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, based on its preliminary internal financial reporting for the fourth quarter 2020, unaudited quarterly revenue is anticipated to be the highest in the Company's history and to surpass analyst estimates.
